Page last updated: 2024-08-17

quinoxalines and Substance-Related Disorders

quinoxalines has been researched along with Substance-Related Disorders in 13 studies

Research

Studies (13)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	5 (38.46)	18.2507
2000's	2 (15.38)	29.6817
2010's	6 (46.15)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Camarasa, J; Ciudad-Roberts, A; Escubedo, E; Pubill, D	1
Booij, J; Crunelle, CL; Miller, ML; van den Brink, W	1
Johnson, TS	1
Grief, SN	1
Marti, J	1
Anthony, JC; Behm, FM; Eaton, WW; Fisher, C; Ialongo, N; Musci, R; Rose, JE; Storr, CL; Uhl, GR; Walther, D	1
Billing, CB; Burstein, AH; McColl, SL; Reeves, KR; Sellers, EM; Stolar, M	1
Tyndale, R	1
Carter, DB; Im, WB; Smith, MW; Tang, AH; VonVoigtlander, PF	1
Steppuhn, KG; Turski, L	1
Belonga, KL; Carter, DB; Im, WB; Jacobsen, EJ; Petke, JD; Sethy, VH; Stelzer, LS; Tang, AH; VonVoigtlander, PF	1
Cervo, L; Samanin, R	1
Harris, LS; Nader, MA; Patrick, GA; Powell, LJ; Winger, G; Woods, JH; Woolverton, WL	1

Reviews

3 review(s) available for quinoxalines and Substance-Related Disorders

Article	Year
The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: a review. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2010, Volume: 20, Issue:2 Topics: Alcohol Drinking; Animals; Behavior, Addictive; Benzazepines; Brain; Dopamine; Drug Partial Agonism; Humans; Neurotransmitter Agents; Nicotinic Agonists; Quinoxalines; Receptors, Nicotinic; Secondary Prevention; Smoking Cessation; Substance-Related Disorders; Varenicline	2010
A brief review of pharmacotherapeutic treatment options in smoking cessation: bupropion versus varenicline. Journal of the American Academy of Nurse Practitioners, 2010, Volume: 22, Issue:10 Topics: Antidepressive Agents, Second-Generation; Behavior Therapy; Benzazepines; Bupropion; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Risk Factors; Smoking Cessation; Smoking Prevention; Substance-Related Disorders; Varenicline	2010
Nicotine dependence: health consequences, smoking cessation therapies, and pharmacotherapy. Primary care, 2011, Volume: 38, Issue:1 Topics: Administration, Cutaneous; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Heart Diseases; Humans; Neoplasms; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; Substance-Related Disorders; Varenicline	2011

Trials

2 trial(s) available for quinoxalines and Substance-Related Disorders

Article	Year
Smoking quit success genotype score predicts quit success and distinct patterns of developmental involvement with common addictive substances. Molecular psychiatry, 2014, Volume: 19, Issue:1 Topics: Adolescent; Benzazepines; Bupropion; Case-Control Studies; Cohort Studies; Dose-Response Relationship, Drug; Female; Genotype; Humans; Male; Nicotine; Outcome Assessment, Health Care; Polymorphism, Single Nucleotide; Quinoxalines; Reproducibility of Results; Risk Factors; Smoking Cessation; Substance-Related Disorders; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline; Young Adult	2014
Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers. Clinical pharmacology and therapeutics, 2008, Volume: 83, Issue:4 Topics: Adult; Amphetamine; Benzazepines; Central Nervous System Stimulants; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Multivariate Analysis; Nicotinic Agonists; Odds Ratio; Quinoxalines; Reproducibility of Results; Smoking; Smoking Cessation; Substance-Related Disorders; Surveys and Questionnaires; Varenicline	2008

Article

Year

Smoking quit success genotype score predicts quit success and distinct patterns of developmental involvement with common addictive substances.

Molecular psychiatry, 2014, Volume: 19, Issue:1

Topics: Adolescent; Benzazepines; Bupropion; Case-Control Studies; Cohort Studies; Dose-Response Relationship, Drug; Female; Genotype; Humans; Male; Nicotine; Outcome Assessment, Health Care; Polymorphism, Single Nucleotide; Quinoxalines; Reproducibility of Results; Risk Factors; Smoking Cessation; Substance-Related Disorders; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline; Young Adult

2014

Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers.

Clinical pharmacology and therapeutics, 2008, Volume: 83, Issue:4

Topics: Adult; Amphetamine; Benzazepines; Central Nervous System Stimulants; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Multivariate Analysis; Nicotinic Agonists; Odds Ratio; Quinoxalines; Reproducibility of Results; Smoking; Smoking Cessation; Substance-Related Disorders; Surveys and Questionnaires; Varenicline

2008

Other Studies

8 other study(ies) available for quinoxalines and Substance-Related Disorders

Article	Year
Heteromeric nicotinic receptors are involved in the sensitization and addictive properties of MDMA in mice. Progress in neuro-psychopharmacology & biological psychiatry, 2013, Jul-01, Volume: 44 Topics: Analysis of Variance; Animals; Benzazepines; Brain; Cholinergic Agents; Conditioning, Operant; Dihydro-beta-Erythroidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Hallucinogens; Hyperkinesis; Male; Mice; Motor Activity; N-Methyl-3,4-methylenedioxyamphetamine; Protein Binding; Quinoxalines; Radionuclide Imaging; Receptors, Nicotinic; Substance-Related Disorders; Tritium; Varenicline	2013
Assessing preferences for improved smoking cessation medications: a discrete choice experiment. The European journal of health economics : HEPAC : health economics in prevention and care, 2012, Volume: 13, Issue:5 Topics: Adolescent; Adult; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Logistic Models; Male; Middle Aged; Models, Econometric; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Substance-Related Disorders; Surveys and Questionnaires; Switzerland; Varenicline; Young Adult	2012
Drug addiction: a critical problem calling for novel solutions. Clinical pharmacology and therapeutics, 2008, Volume: 83, Issue:4 Topics: Benzazepines; Buprenorphine; Bupropion; Chronic Disease; Financing, Government; Genetic Testing; Harm Reduction; Humans; Marijuana Smoking; Naltrexone; Narcotic Antagonists; Prevalence; Privacy; Quinoxalines; Receptors, Nicotinic; Recurrence; Risk-Taking; Smoking; Smoking Cessation; Smoking Prevention; Social Environment; Substance-Related Disorders; Varenicline	2008
U-90042, a sedative/hypnotic compound that interacts differentially with the GABAA receptor subtypes. The Journal of pharmacology and experimental therapeutics, 1995, Volume: 275, Issue:2 Topics: Animals; Avoidance Learning; Benzodiazepines; Discrimination Learning; Ethanol; Female; Hypnotics and Sedatives; Macaca mulatta; Male; Mice; Motor Activity; Oxadiazoles; Quinoxalines; Rats; Rats, Inbred F344; Receptors, GABA; Recombinant Proteins; Substance-Related Disorders	1995
Diazepam dependence prevented by glutamate antagonists. Proceedings of the National Academy of Sciences of the United States of America, 1993, Jul-15, Volume: 90, Issue:14 Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Diazepam; Drug Tolerance; Electroencephalography; Electromyography; Excitatory Amino Acid Antagonists; Male; Mice; Mice, Inbred Strains; Motor Activity; Muscle Tonus; Piperazines; Quinoxalines; Seizures; Substance Withdrawal Syndrome; Substance-Related Disorders; Time Factors	1993
3-Phenyl-substituted imidazo[1,5-alpha]quinoxalin-4-ones and imidazo[1,5-alpha]quinoxaline ureas that have high affinity at the GABAA/benzodiazepine receptor complex. Journal of medicinal chemistry, 1996, Sep-13, Volume: 39, Issue:19 Topics: Animals; Anticonvulsants; Benzodiazepines; Cell Membrane; Cerebral Cortex; Drug Synergism; Ethanol; Imidazoles; Ligands; Male; Mice; Molecular Conformation; Molecular Structure; Pentylenetetrazole; Quinoxalines; Rats; Receptors, GABA; Seizures; Structure-Activity Relationship; Substance-Related Disorders	1996
Effects of dopaminergic and glutamatergic receptor antagonists on the establishment and expression of conditioned locomotion to cocaine in rats. Brain research, 1996, Aug-26, Volume: 731, Issue:1-2 Topics: Analysis of Variance; Animals; Benzazepines; Cocaine; Conditioning, Psychological; Dizocilpine Maleate; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dopamine Uptake Inhibitors; Excitatory Amino Acid Antagonists; Locomotion; Male; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Kainic Acid; Receptors, N-Methyl-D-Aspartate; Recurrence; Substance-Related Disorders; Sulpiride	1996
Progress report from the Testing Program for Stimulant and Depressant Drugs (1991). NIDA research monograph, 1992, Volume: 119 Topics: Animals; Anti-Anxiety Agents; Central Nervous System Depressants; Central Nervous System Stimulants; Discrimination, Psychological; Female; Flunitrazepam; Humans; Macaca mulatta; Male; Mice; Nitrazepam; Oxadiazoles; Quinoxalines; Rats; Rats, Sprague-Dawley; Self Administration; Substance-Related Disorders	1992